A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above

NCT05059301 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

770

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSVPreF3 OA investigational vaccine

Sponsor

GlaxoSmithKline